Asia Pacific Molecular Diagnostics Market worth $7.58 billion by 2031
The report "Asia Pacific Molecular Diagnostics Market by Product & Services (Kits, Instruments), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH), Application [Infectious (Hepatitis, HIV, HAI, Flu), Cancer (Breast, Lung)] - Forecast to 2031" is projected to grow from USD 4.22 billion in 2026 and to reach USD 7.58 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 12.4% during the forecast period.
Browse 150 market data Tables and 44 Figures spread through 200 Pages and in-depth TOC on "Asia Pacific Molecular Diagnostics Market by Product & Services (Kits, Instruments), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH), Application [Infectious (Hepatitis, HIV, HAI, Flu), Cancer (Breast, Lung)] - Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/apac-molecular-diagnostics-market-214582941.html
Some of the key factors propelling the Asia Pacific molecular diagnostics market include the higher prevalence of infectious diseases and the rising incidence of cancer, thereby driving the need for accurate diagnostic tests. Additionally, rising awareness among patients regarding the early detection of diseases, combined with easier access to healthcare facilities, is also driving the molecular diagnostics market. Moreover, rising healthcare expenditures, coupled with government initiatives aimed at improving diagnostic capabilities, are also positively driving this market.
The reagents & kits segment held the largest share of the Asia Pacific molecular diagnostics market, by product & service, in 2025.
On the basis of product & service, the market is segmented into reagents & kits, instruments, and services & software. In 2025, reagents & kits accounted for the largest share, supported by their recurring use in every molecular diagnostic test performed. High testing volumes across infectious diseases & oncology, along with the expanding availability of assay kits tailored to regional disease profiles, resulted in consistent demand. Additionally, the need for regular replenishment of consumables and the ongoing introduction of new assay formats contribute to the segment’s dominant market position.
The oncology testing segment is expected to be the fastest-growing segment, by application, during the forecast period.
Based on application, the market is segmented into infectious disease diagnostics, oncology testing, genetic testing, and other applications. Among these, the oncology testing segment is expected to register the highest growth rate, driven by the increasing incidence of cancer and the growing use of molecular diagnostics for tumor characterization and treatment selection. The wider adoption of precision medicine approaches and the increasing availability of advanced molecular assays are further supporting the rapid growth of the oncology testing segment.
The major players operating in this market are Danaher (US), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (US), bioMérieux (France), Thermo Fisher Scientific Inc. (US), Hologic, Inc. (US), Abbott (US), Siemens Healthineers AG (Germany), QIAGEN (Netherlands), and Becton, Dickinson and Company (US).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Asia Pacific Molecular Diagnostics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
